Budesonide added to modified porcine surfactant Curosurf may additionally improve the lung functions in meconium aspiration syndrome.

Abstract

Severe meconium aspiration syndrome (MAS) in newborns is often treated by exogenous surfactant. Because its efficacy is reduced by meconium-induced inflammation, glucocorticoid budesonide was added into surfactant preparation Curosurf to enhance efficacy of the surfactant therapy in experimental model of MAS. Oxygen-ventilated rabbits were intratracheally given meconium (25 mg/ml, 4 ml/kg) to induce respiratory failure. Thirty minutes later, animals were treated by intratracheal budesonide (0.25 mg/kg) or surfactant lung lavage (10 ml/kg, 5 mg phospholipids/ml) repeated twice, followed by undiluted Curosurf (100 mg phospholipids/kg) or by the above mentioned surfactant treatment with the last surfactant dose fortified with budesonide (0.25 mg/kg) or were untreated. Animals were ventilated for additional 5 hours and respiratory parameters were measured regularly. After sacrificing animals, wet-dry lung weight ratio was evaluated and plasma levels of interleukins (IL)-1beta, -6, -8, and TNF-alpha were measured by ELISA method. Efficacy of the given therapies to enhance lung functions and to diminish lung edema formation and inflammation increased from budesonide-only and surfactant-only therapy to surfactant+budesonide therapy. Combined therapy improved gas exchange from 30 min of administration, and showed a longer-lasting effect than surfactant-only therapy. In conclusions, budesonide additionally improved the effects of exogenous surfactant in experimental MAS.

• Authors: P Mikolka, D Mokrá, J Kopincová, L Tomčíková-Mikušiaková, A Calkovská
• Journal: Physiological research (Physiol Res) Vol. 62 Issue Suppl 1 Pg. S191-200 ( 2013) ISSN: 1802-9973 [Electronic] Czech Republic
• PMID: 24329699 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Inflammatory Agents
• Biological Products
• Bronchodilator Agents
• Drug Combinations
• Immunologic Factors
• Phospholipids
• Pulmonary Surfactants
• Budesonide
• poractant alfa

Topics

• Animals
• Anti-Inflammatory Agents (administration & dosage)
• Biological Products (administration & dosage)
• Bronchodilator Agents (administration & dosage)
• Budesonide (administration & dosage)
• Drug Combinations
• Drug Synergism
• Female
• Immunologic Factors (metabolism)
• Male
• Meconium Aspiration Syndrome (diagnosis, drug therapy, physiopathology)
• Phospholipids (administration & dosage)
• Pulmonary Surfactants
• Rabbits
• Respiratory Mechanics (drug effects)
• Swine
• Treatment Outcome